Clinical Trial Update: A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis [Phase 2]

View source ↗

Summary

Phase 2 study evaluating tolerability and efficacy of navitoclax alone or in combination with ruxolitinib in myelofibrosis has completed and results have been p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis

Drugs mentioned

• Navitoclax (navitoclax)
• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: AbbVie | Conditions: Myelofibrosis (MF) | Phase 2 | Status: COMPLETED | Results posted: 2025-03-12